Lebsa Shareholders Meet: Tradition And Innovation To Drive Company Growth
Lebsa and Selectchemie Join Forces at CPHI Barcelona to Drive Innovation in the Pharmaceutical Industry
Octenidine Dihydrochloride API: The Challenge for Lebsa in 2023
Renewed Gold EcoVadis Medal Award 2022
What Is Coming Next?
Presenting “Entenent LEBSA”: our origins, values and philosophy
One of the critical values of Lebsa is to provide regulatory support and keep updated our partners and clients about it. We are pleased to announce that we have received a new CEP from the European Directorate for the Quality Medicines (EDQM) on Dec 6th of 2021. In this case, it is for the API Mianserin Hydrochloride.
Since Dr. Josep Maria Espinós founded Lebsa in 1951, we have served the pharmaceutical industry by manufacturing niche Active Pharmaceutical Ingredients (APIs) with the highest quality, rigour, and service.
The public health emergency triggered by COVID-19 is not only a matter of respiratory distress and ICU admissions. It has also led to an unprecedented breakout of mental health problems worldwide. Doctors in the emergency room are receiving more anxiety cases than ever, causing frequent flare-ups of gastrointestinal symptoms, asthma, and more.
In LEBSA, we are proud to report the recent updates about our products and services to our clients. This time, we are glad to inform our partners and customers that the European Directorate for the Quality of Medicines (EDQM) has granted a CEP to our API Dequalinium Chloride on Dec 18th, 2020.